ATE535523T1 - Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten - Google Patents

Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten

Info

Publication number
ATE535523T1
ATE535523T1 AT06760341T AT06760341T ATE535523T1 AT E535523 T1 ATE535523 T1 AT E535523T1 AT 06760341 T AT06760341 T AT 06760341T AT 06760341 T AT06760341 T AT 06760341T AT E535523 T1 ATE535523 T1 AT E535523T1
Authority
AT
Austria
Prior art keywords
benzimidazolecarbonic
acid amide
receptor agonists
amide compounds
compounds
Prior art date
Application number
AT06760341T
Other languages
English (en)
Inventor
Robert Mckinnell
Roland Gendron
Lan Jiang
Seok-Ki Choi
Daniel Long
Paul Fatheree
Daniel Marquess
Sean Dalziel
Kirsten Phizackerley
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE535523(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE535523T1 publication Critical patent/ATE535523T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06760341T 2005-05-25 2006-05-24 Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten ATE535523T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68446605P 2005-05-25 2005-05-25
US68447805P 2005-05-25 2005-05-25
US74841505P 2005-12-08 2005-12-08
PCT/US2006/020085 WO2006127815A2 (en) 2005-05-25 2006-05-24 Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Publications (1)

Publication Number Publication Date
ATE535523T1 true ATE535523T1 (de) 2011-12-15

Family

ID=37452788

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06760341T ATE535523T1 (de) 2005-05-25 2006-05-24 Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten

Country Status (26)

Country Link
US (10) US7759363B2 (de)
EP (1) EP1899324B1 (de)
JP (2) JP5072111B2 (de)
KR (1) KR101333280B1 (de)
AR (1) AR057327A1 (de)
AT (1) ATE535523T1 (de)
AU (1) AU2006250009B2 (de)
BR (1) BRPI0611202C1 (de)
CA (1) CA2607280C (de)
CY (1) CY1112366T1 (de)
DK (1) DK1899324T3 (de)
EA (1) EA013240B1 (de)
ES (1) ES2376115T3 (de)
HR (1) HRP20120108T2 (de)
IL (1) IL186883A (de)
MA (1) MA29541B1 (de)
MX (1) MX2007014762A (de)
MY (1) MY147756A (de)
NO (1) NO339658B1 (de)
NZ (1) NZ563068A (de)
PE (1) PE20061446A1 (de)
PL (1) PL1899324T3 (de)
PT (1) PT1899324E (de)
SI (1) SI1899324T1 (de)
TW (1) TWI388555B (de)
WO (1) WO2006127815A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537127C (en) * 2003-09-03 2011-04-05 Pfizer Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AU2010229142A1 (en) 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
BRPI1013777A8 (pt) * 2009-04-13 2017-09-19 Theravance Biopharma R&D Ip Llc Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP3031802A4 (de) * 2013-08-09 2017-07-12 Santen Pharmaceutical Co., Ltd Herstellungsverfahren für 3,3-dimethyl-3,4-dihydro-1h-chinoxalin-2-on-derivat und zwischenprodukt für besagtes herstellungsverfahren

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
JPH111472A (ja) 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
US6294555B1 (en) 1998-04-28 2001-09-25 Dainippon Pharmaceutical Co., Ltd. 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
EP1391457B1 (de) 1998-11-03 2013-12-25 AbbVie Deutschland GmbH & Co KG Substituierte 2-Phenylbenzimidazole und deren Verwendung als PARP Inhibitoren
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JP2001122784A (ja) 1999-10-27 2001-05-08 Dainippon Pharmaceut Co Ltd １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
AU2001275326C1 (en) * 2000-06-07 2006-09-21 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
DK1546134T3 (da) 2002-08-05 2007-09-10 Lilly Co Eli Piperazinsubstituerede arylbenzodiazepiner
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277320A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
CA2537127C (en) * 2003-09-03 2011-04-05 Pfizer Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7256294B2 (en) 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound

Also Published As

Publication number Publication date
US20090209582A1 (en) 2009-08-20
NZ563068A (en) 2011-01-28
JP2012197322A (ja) 2012-10-18
EA200702612A1 (ru) 2008-06-30
AU2006250009B2 (en) 2012-03-08
EA013240B1 (ru) 2010-04-30
JP2008542281A (ja) 2008-11-27
NO339658B1 (no) 2017-01-16
KR101333280B1 (ko) 2013-11-28
BRPI0611202B8 (pt) 2019-09-24
US10233172B2 (en) 2019-03-19
US20060270652A1 (en) 2006-11-30
CA2607280A1 (en) 2006-11-30
US20130273568A1 (en) 2013-10-17
MY147756A (en) 2013-01-15
US20170081313A1 (en) 2017-03-23
US20190152951A1 (en) 2019-05-23
HRP20120108T2 (hr) 2012-03-31
BRPI0611202C1 (pt) 2021-05-25
US10696656B2 (en) 2020-06-30
HK1110980A1 (en) 2008-07-25
US11254655B2 (en) 2022-02-22
WO2006127815A2 (en) 2006-11-30
US20200283408A1 (en) 2020-09-10
US9975877B2 (en) 2018-05-22
MX2007014762A (es) 2008-02-14
TWI388555B (zh) 2013-03-11
WO2006127815A3 (en) 2007-08-02
KR20080021045A (ko) 2008-03-06
TW200716607A (en) 2007-05-01
DK1899324T3 (da) 2012-02-13
PL1899324T3 (pl) 2012-04-30
PT1899324E (pt) 2012-01-24
IL186883A0 (en) 2008-02-09
EP1899324A2 (de) 2008-03-19
SI1899324T1 (sl) 2012-03-30
HRP20120108T1 (en) 2012-02-29
ES2376115T3 (es) 2012-03-09
AU2006250009A1 (en) 2006-11-30
US20180237420A1 (en) 2018-08-23
NO20076481L (no) 2007-12-17
BRPI0611202A2 (pt) 2010-08-24
US8143279B2 (en) 2012-03-27
US9428489B2 (en) 2016-08-30
PE20061446A1 (es) 2007-01-16
CA2607280C (en) 2013-09-17
EP1899324B1 (de) 2011-11-30
AR057327A1 (es) 2007-11-28
JP5072111B2 (ja) 2012-11-14
MA29541B1 (fr) 2008-06-02
IL186883A (en) 2013-03-24
US20220274957A1 (en) 2022-09-01
US7759363B2 (en) 2010-07-20
CY1112366T1 (el) 2015-12-09
BRPI0611202B1 (pt) 2019-09-24
US20100249186A1 (en) 2010-09-30
US20150183761A1 (en) 2015-07-02
US8377964B2 (en) 2013-02-19

Similar Documents

Publication Publication Date Title
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
ATE504559T1 (de) Arylanilinderivate als agonisten des beta2- adrenergen rezeptors
ATE435207T1 (de) Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
EP2079466A4 (de) Substituierte indolverbindungen
ATE509927T1 (de) Indolderivate als s1p1-rezeptor-agonisten
DK1919907T5 (da) Heterocyklisk forbindelse
CY2013047I2 (el) Ενωσεις διαρυλυδαντοϊνης
ATE513827T1 (de) Oxyindol-derivate als 5ht4-rezeptor-agonisten
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
DE602006003628D1 (de) Purinderivate als a2a-rezeptoragonisten
IL186883A0 (en) Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
DK1937650T3 (da) Heterocykliske forbindelser
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
ATE443056T1 (de) Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
ATE435225T1 (de) Oxadiazolonderivate als ppar-delta-agonisten
ZA200707142B (en) Quinolinone compounds as 5-HT4 receptor agonists
DK1931309T3 (da) Antimykotisk sammensætning
ATE469900T1 (de) Spiropiperidinderivate als antagonisten des via- rezeptors
ATE459618T1 (de) 3-piperidinylisochroman-5-ole als dopaminagonisten